Comparative Pharmacology
Head-to-head clinical analysis: CYTADREN versus FEMARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTADREN versus FEMARA.
CYTADREN vs FEMARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone, thereby blocking adrenal steroidogenesis. It also inhibits aromatase, reducing estrogen synthesis.
Aromatase inhibitor; inhibits the conversion of androgens to estrogens by competitively binding to the aromatase enzyme, thereby reducing estrogen levels in peripheral tissues and tumors.
200 mg orally once daily
2.5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 3–4 hours in adults with normal renal function; prolonged to 8–12 hours in end-stage renal disease.
The terminal elimination half-life of letrozole is approximately 2 days (range 24–48 hours). Steady-state concentrations are achieved within 2–6 weeks of daily dosing. The long half-life supports once-daily dosing.
Renal: ~60% as unchanged drug; biliary/fecal: ~25% as metabolites; minor via respiration.
Letrozole is extensively metabolized in the liver, primarily to an inactive carbinol metabolite. Approximately 90% of an oral dose is excreted in urine, with about 6% as unchanged drug and 84% as metabolites. Fecal excretion accounts for less than 10%.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor